Biochimica et Biophysica Acta-Reviews on Cancer

Article	Citations
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting	241
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer	192
Advances in clinical immunotherapy for gastric cancer	188
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter	173
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer	159
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics	158
Non-coding RNAs and potential therapeutic targeting in cancer	143
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.	130
Progress and challenges of immunotherapy in triple-negative breast cancer	121
Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives	113
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside	113
The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential	102
HER2-targeted therapies in gastric cancer	94
Tumor-associated neutrophils and neutrophil-targeted cancer therapies	89
Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer	87
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy	81
Metabolic reprogramming in renal cancer: Events of a metabolic disease	76
The role of N6-methyladenosine mRNA in the tumor microenvironment	75
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal	74
Genomic instability, inflammatory signaling and response to cancer immunotherapy	74
Targeting tumor-associated macrophages for cancer immunotherapy	73
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications	69
GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment	66
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer	65
DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer	64

Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors	61
The clinical relevance of gene expression based prognostic signatures in colorectal cancer	61
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers	58
Combinatorial therapy in tumor microenvironment: Where do we stand?	58
LOXL2 in cancer: regulation, downstream effectors and novel roles	57
Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis	57
Targeting Bcl-2 for cancer therapy	57
PTEN in osteosarcoma: Recent advances and the therapeutic potential	55
Immunotherapy for advanced hepatocellular carcinoma, where are we?	53
Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications	53
Non-mitotic functions of polo-like kinases in cancer cells	52
CCR7 as a therapeutic target in Cancer	52
Cyclin-dependent kinases in DNA damage response	50
SOX9: An emerging driving factor from cancer progression to drug resistance	49
Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression	49
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer	48
SOS GEFs in health and disease	48
Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy	48
Nerve input to tumours: Pathophysiological consequences of a dynamic relationship	47
The emerging role of miRNA clusters in breast cancer progression	46
Recent advances in organoid development and applications in disease modeling	46
The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction	45
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities	45
Cancer regeneration: Polyploid cells are the key drivers of tumor progression	44
Resistin: An inflammatory cytokine with multi-faceted roles in cancer	43
RUNX1 and cancer	43
The progress of immune checkpoint therapy in primary liver cancer	43
Organoid model: A new hope for pancreatic cancer treatment?	42
Mitochondria: The metabolic switch of cellular oncogenic transformation	42
Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer	41
Drug resistance in colorectal cancer: An epigenetic overview	41
Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma	41
Metabolic tricks of cancer cells	40
Modeling pancreatic cancer in mice for experimental therapeutics	39
Cross talk between autophagy and oncogenic signaling pathways and implications for cancer therapy	39
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy	38
Role of tyrosine phosphorylation in modulating cancer cell metabolism	38
Human MYC G-quadruplex: From discovery to a cancer therapeutic target	38
A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors	37
MCM family in gastrointestinal cancer and other malignancies: From functional characterization to clinical implication	37
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents	37
MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential	37
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore	37
The outstanding antitumor capacity of CD4+ T helper lymphocytes	37
Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model	37
Role of gut microbiota in epigenetic regulation of colorectal Cancer	36
The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma	36
Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing	35
Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles	35
The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma	35

Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer	35
EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy	34
Odors and cancer: Current status and future directions	33
Pathogenesis and therapeutic strategy in platinum resistance lung cancer	33
HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology	33
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression	32
S100A8 and S100A9 in Cancer	32
Mitochondrial dynamics, a new therapeutic target for Triple Negative Breast Cancer	32
Closing the translation gap: AI applications in digital pathology	32
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer	32
Mesenchymal stem cells in glioblastoma therapy and progression: How one cell does it all	32
Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs	32
New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies	32
The multifaceted roles of gasdermins in cancer biology and oncologic therapies	31
DNA damage response inhibitors: An avenue for TNBC treatment	31
Platinum-based systematic therapy in triple-negative breast cancer	31
Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission	31
A “hit-and-run” affair – A possible link for cancer progression in virally driven cancers	31
Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression	31
The use of nanotechnology to combat liver cancer: Progress and perspectives	29
Metabolic heterogeneity in cancer: An overview and therapeutic implications	29
Inhibiting homologous recombination by targeting RAD51 protein	29
Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy	29
The evolution and ecology of benign tumors	29
Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance	29
Protein phosphatase 1 in tumorigenesis: is it worth a closer look?	29
EpCAM cellular functions in adhesion and migration, and potential impact on invasion: A critical review	28
Gut mycobiome: A promising target for colorectal cancer	28
P53 in skin cancer: From a master player to a privileged target for prevention and therapy	28
Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance	27
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?	27
CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer	27
Colorectal cancer: Metabolic interactions reshape the tumor microenvironment	26
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology	26
Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer	26
Diffuse gastric cancer: Emerging mechanisms of tumor initiation and progression	26
Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers	26
Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer	26
Peptides that immunoactivate the tumor microenvironment	25
Biosensors as diagnostic tools in clinical applications	25
Multifaceted roles of HSF1 in cell death: A state-of-the-art review	25
Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis	25
Small extracellular vesicles (exosomes) and their cargo in pancreatic cancer: Key roles in the hallmarks of cancer	25
Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy	25
Interstitial fluid pressure as an emerging biomarker in solid tumors	25
Centrosome amplification in cancer and cancer-associated human diseases	24
Exosomes: The protagonists in the tale of colorectal cancer?	24
Can EGFR be a therapeutic target in breast cancer?	24
Pericytes cross-talks within the tumor microenvironment	24
miRNAs and androgen deprivation therapy for prostate cancer	24
Small nucleolar RNA and its potential role in breast cancer – A comprehensive review	23
Targeting Cdc20 for cancer therapy	23
The role of m6A modification in pediatric cancer	23
Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies	23
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab	23
The role of DNA damage and repair in liver cancer	23
Unfolding the cascade of SERPINA3: Inflammation to cancer	23
Balancing neurotrophin pathway and sortilin function: Its role in human disease	22
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies	22
The Epigenetic landscape of Circulating tumour cells	22
Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy	22
How to evaluate deep learning for cancer diagnostics – factors and recommendations	22
Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression	21
Matrix stiffness and its influence on pancreatic diseases	21
Tumoral heterogeneity in neuroblastoma	21
Platelet cancer cell interplay as a new therapeutic target	21
Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma	21
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors	21
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway	21
Oxygen gradient and tumor heterogeneity: The chronicle of a toxic relationship	20
The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients	20
Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application	20
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials	20
Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs	19
The role of autophagy in pancreatic cancer progression	19
Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer	19
Ductal metaplasia in pancreas	19
The interaction of SET and protein phosphatase 2A as target for cancer therapy	19
Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives	19
The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors	19

In vitro anticancer properties of anthocyanins: A systematic review	19
The impact of HPV infection on human glycogen and lipid metabolism – a review	19
Consequence of distinctive expression of MUC2 in colorectal cancers: How much is actually bad?	19
The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation	19
PDLIM2: Signaling pathways and functions in cancer suppression and host immunity	19
The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer	19
Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer	19
CD47: Beyond an immune checkpoint in cancer treatment	18
The signaling pathways regulated by KRAB zinc-finger proteins in cancer	18
Two decades of a protooncogene HPIP/PBXIP1: Uncovering the tale from germ cell to cancer	18
Extracellular proteolysis in glioblastoma progression and therapeutics	18
Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer	18
Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis	18